<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04574505</url>
  </required_header>
  <id_info>
    <org_study_id>SCH 01/2020</org_study_id>
    <nct_id>NCT04574505</nct_id>
  </id_info>
  <brief_title>Food Supplementation With Eufortyn Colesterolo Plus for LDL Modulation in Subjects With Polygenic Hypercholesterolemia</brief_title>
  <acronym>ANEMONE</acronym>
  <official_title>Evaluation of the Effect of a Food Supplementation With Eufortyn Colesterolo Plus on the Modulation of LDL Cholesterolemia in Subjects Affected by Polygenic Hypercholesterolemia: a Two-arm Double-blind, Placebo- Controlled, Randomized, Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Bologna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SCHARPER Spa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Bologna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a two-arm randomized, placebo-controlled, double-blind, monocentric parallel-groups&#xD;
      clinical study conducted in Italy.&#xD;
&#xD;
      The objective of this study is to evaluate the effect of dietary supplementation of a&#xD;
      combined supplement containing bergamot (Vazguard®) phytosomal polyphenolic fraction&#xD;
      associated with standardized artichoke extract (Pycrinil®, Cynara cardunculus) and Cynara&#xD;
      scolimus, associated with high coenzyme Q10 bioavailability (Q10 phytosome® Ubiqsome) and&#xD;
      zinc, on the glycometabolic structure of subjects with suboptimal levels of LDL&#xD;
      cholesterolemia compared with placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 14, 2020</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a two-arm randomized, placebo-controlled, double-blind, monocentric parallel-groups clinical study conducted in Italy.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective is to compare the effect on total cholesterol after 8 weeks of treatment with a combined food supplement with placebo (standard diet only).</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>NUT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 tablet of Eufortyn Colesterolo Plus per day + standard diet for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 tablet of Placebo per day + standard diet for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Eufortyn Colesterolo Plus</intervention_name>
    <description>Food supplement combination containing bergamot (Vazguard®) phytosomal polyphenolic fraction associated with standardized artichoke extract (Pycrinil®, Cynara Cardunculus L) and Cynara scolimus, associated with high coenzyme Q10 bioavailability(Q10 phytosome® Ubiqsome) and zinc.</description>
    <arm_group_label>NUT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects agree to participate in the study and having dated and signed the informed&#xD;
             consent form.&#xD;
&#xD;
          -  Subjects who have the capability to communicate, to make themselves understood, and to&#xD;
             comply with the study's requirements.&#xD;
&#xD;
          -  Male or female aged ≥ 18 years and ≤ 70 years old.&#xD;
&#xD;
          -  LDL-Cholesterol plasma levels &gt;115 mg/dL and &lt; 190 mg/dL.&#xD;
&#xD;
          -  TG&lt;400 mg/dL.&#xD;
&#xD;
          -  Subjects who, according to the SCORE charts, have a low or moderate cardiovascular&#xD;
             risk (defined as a total cardiovascular risk &lt; 5%) and for whom, according to ESC/EAS&#xD;
             guidelines 2019, the intervention strategy does not require a pharmacological lipid&#xD;
             lowering intervention.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects already affected by cardiovascular diseases (secondary prevention) or with&#xD;
             estimated 10 years cardiovascular disease risk&gt; 5%;&#xD;
&#xD;
          -  Obesity (BMI&gt;30 kg/m2) or diabetes mellitus;&#xD;
&#xD;
          -  Assumption of lipid lowering drugs or food supplements, or drugs potentially affecting&#xD;
             the lipid metabolism;&#xD;
&#xD;
          -  Antihypertensive treatment not stabilized since at least 3 months;&#xD;
&#xD;
          -  Anticoagulants therapy&#xD;
&#xD;
          -  Uncontrolled hypertension (systolic blood pressure&gt; 190 mmHg or diastolic arterial&#xD;
             pressure&gt; 100 mmHg);&#xD;
&#xD;
          -  Known current thyroid, gastrointestinal or hepatobiliary diseases;&#xD;
&#xD;
          -  Any medical or surgical condition that would limit the patient adhesion to the study&#xD;
             protocol;&#xD;
&#xD;
          -  Abuse of alcohol or drugs (current or previous);&#xD;
&#xD;
          -  History of malignant neoplasia in the 5 years prior to enrolment in the study;&#xD;
&#xD;
          -  History or clinical evidence of inflammatory disease such as severe arthritis,&#xD;
             systemic lupus erythematosus or chronic inflammatory diseases or current therapy with&#xD;
             immunosuppressive agents or long-term glucocorticoids;&#xD;
&#xD;
          -  History or clinical evidence of any significant concomitant disease that could&#xD;
             compromise the safety of the subject or the possibility of completing the study;&#xD;
&#xD;
          -  Known previous intolerance to one component of the tested nutraceuticals&#xD;
&#xD;
          -  Women in fertile age not using consolidated contraceptive methods&#xD;
&#xD;
          -  Pregnancy and Breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arrigo Cicero, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Bologna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arrigo Cicero, MD</last_name>
    <phone>++39 512142224</phone>
    <email>arrigo.cicero@unibo.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>AOU Policlinico S.Orsola-Malpighi</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arrigo Cicero, MD</last_name>
      <email>arrigo.cicero@unibo.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 14, 2020</study_first_submitted>
  <study_first_submitted_qc>September 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2020</study_first_posted>
  <last_update_submitted>September 28, 2020</last_update_submitted>
  <last_update_submitted_qc>September 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Bologna</investigator_affiliation>
    <investigator_full_name>Arrigo F.G. Cicero</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

